Mental health EPD Osmind scored $40 million in a Series B funding round led by DFJ Growth.
Other participants include Susa Ventures, General Catalyst, Future Ventures, Tiger Global, Pear VC and Angels Lachy Groom, Brent Saunders, Helena Goodman and Ariel Katz.
Osmind offers a tailored EHR for clinicians and researchers using and studying ketamine and other psychedelics, as well as transcranial magnetic stimulation for treatment-resistant depression. The latest round brings the startup’s total revenue to $57 million.
Osmind said it plans to use the capital to further develop and scale its EHR, conduct research with new partners and more than double the size of its team.
“Osmind supports clinicians treating patients with severe and intractable mental health conditions, including major depression, suicidality, PTSD, substance use disorders, anxiety, OCD and more,” said co-founder and COO Jimmy Qian in a statement. “By enabling the serious innovation led by interventional mental health practices, we are doing our part to help researchers expand better, safer, and more effective treatments for patients who need it most.”
Israel-based precision oncology platform OncoHost has raised $35 million in Series C funding.
The round was led by ALIVE Israel HealthTech VC with the participation of Leumi Partners, Menora Mivtachim, OurCrowd and existing investors. Funding will go towards expanding the business clinical trial using the PROphet platform to better predict a patient’s response to cancer treatment.
“This is OncoHost’s third and most significant investment round to date, demonstrating the company’s maturity, credibility and scalability,” said CEO Dr. Ofer Sharon in a statement. “We are honored to be backed by leading local and global investment funds who understand and support our vision to transform the landscape of oncology into a truly personalized approach and who want to be part of our journey to revolutionize cancer care.”
Tech-enabled home care startup Revence emerged from stealth with $9.5 million from a funding round led by Target Global.
Reverence also announced that it has acquired the automated workforce platform Hirehand. The company works with groups of caregivers to optimize which caregivers they send to a patient’s home at the right time. The platform also allows them to share data with other clinicians and family members involved in home care, and creates condition-specific checklists for caregivers.
“We have only scratched the surface of how home care models can improve and save lives,” founder and CEO Lee Hudson Teslik said in a statement. “Our technology provides the connective tissue needed to bridge the gap between hospital and home † unlocking new possibilities and paving the way for a stronger, more sustainable and clinically more effective future for home care.”
Virtual pediatric behavioral health startup Handspring Health completed a $6.2 million seed round led by Newark Venture Partners and NextView Ventures.
Other participants in the round include 25madison Ventures, Arkitekt Ventures and Quantum Angels. The company currently offers virtual therapy for children ages 10 to 17 in New Jersey. Handspring plans to start seeing younger patients in in-person clinics across the state. The seed investment is intended to support the process.
The startup also plans to use the funding to hire more clinicians, invest in their technology and patient experience, partner with payers and expand into new markets.
“The health care system is failing our children because systemic barriers have made it impossible for families to find care that is accessible. When seeking care, families are often faced with unaffordable rates that are not covered by insurance, or waiting lists that last several months.” co-founder and CEO Sahil Choudhry in a statement. “In addition, most of the new solutions currently on the market are only virtual; not all children can be treated virtually, and many require more hands-on and personalized attention.”
Digital Mental Health Company Meru Health received a $2 million grant from the National Institute of Mental Health to study the effectiveness of its 12-week app-based program for primary care patients.
“The importance of this study is enormous,” said Dr. Nicholas Peiper, principal investigator and research director at Meru Health, said in a statement. “We use gold standard methods to determine the effectiveness of the Meru Health Program. Conducting this primary care research is also a big step, as the majority of people with depression seek help from their primary care provider in the first instance.”
Meru most recently raised $38 million in Series B financing in September.